This work underscores the potential of host-directed therapeutics, in conjunction with antibiotics, to improve treatment outcomes
Nhng vi cc sn phm Liposome Glutathione, th cc cht xc tc ny v c bn l khng cn thit na v Glutathione c mng Liposome bo v nn kh nng hp th gn nh tuyt i, vo thng h tun hon lun m khng b ph hy, hiu qu tng ng truyn trng
doi: 10.3389/fendo.2023.1269266 Summary Keywords epigenetic modifications, gut microbiota, metabolic dysfunction, polycystic ovary syndrome, therapeutic targets and drugs Citation Chen Y, Sun X, Xia X, Chen K and Zeng F (2026) The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome
L., von Karstedt, S., Lockwood, W
In vitro studies show that Mst1, transcriptionally activated by the nuclear receptor NR4A, translocates to the nucleus, where it interacts with p53 to promote Drp1 gene expression and Drp1 phosphorylation at Ser616, thereby inducing excessive mitochondrial fragmentation
PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC 50 of 4.8 nM in A549 cell line, sensitive to oncogenic mutations (no activity to Y1230C mutant)
